Chimerix Appoints Lisa Decker to Board of Directors
December 29 2023 - 7:00AM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission
is to develop medicines that meaningfully improve and extend the
lives of patients facing deadly diseases, today announced Lisa
Decker, Chief Business Officer at IGM Biosciences, has been
appointed to Chimerix's Board of Directors. Ms. Decker replaces
Catherine Gilliss PhD, RN, FAAN, who is simultaneously retiring
from the Chimerix Board after nearly 10 years of service.
“We are delighted to welcome Lisa to the Chimerix Board of
Directors. She brings a wealth of scientific expertise, oncology
drug development and business development experience that will be
important assets to Chimerix as we advance our pipeline toward
commercialization,” said Mike Andriole, Chief Executive Officer
of Chimerix. “We also thank Catherine for her valuable
insight and judgement to the Chimerix Board over her tenure and for
the impact she has had on the company during that time. Chimerix is
well positioned for the years ahead and we thank her for her many
contributions over her nearly decade of service.”
Prior to her role at IGM Biosciences, Ms. Decker was Chief
Business Officer at Atreca Inc., where she oversaw the business
development and alliance management functions. Before that, she
served in multiple roles at Nektar Therapeutics, most recently
serving as Vice President, Business Development. Earlier, she
served as Associate Director in the Office of Technology Management
at the University of Massachusetts Medical School. Ms. Decker
received her Ph.D. in Immunology from Tufts University School of
Medicine and her B.A. in Biology from the College of the Holy
Cross.
About Chimerix Chimerix is a biopharmaceutical
company with a mission to develop medicines that meaningfully
improve and extend the lives of patients facing deadly diseases.
The Company’s most advanced clinical-stage development program,
ONC201, is in development for H3 K27M-mutant glioma.
CONTACT:Will O’ConnorStern Investor
Relations212-362-1200ir@chimerix.com
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Apr 2023 to Apr 2024